IR
Superintel
OverviewMarketsWatchlist
© 2026 IR SuperintelMethodologyContact

Cytomed Therapeutics Limited (GDTC)

CUSIP: Y1R80M106 | Healthcare · Biotechnology | Micro Cap | 12 institutional holders

Quarters

Q3 2026Q2 2026Q1 2026Q4 2025Q3 2025
CompareDetailedHistoricalFundsOptionsShort Interest13D/13GPeersTargetingTrading SummaryProfile

Beneficial Ownership — 13D / 13G

Full history →

5%+ stakes reported outside the quarterly cycle. A 13D is due within five business days of the event below, so these figures lead the holders table until the filer's next 13F catches up to them.

HolderShares% of ClassChangeEvent Datevs 13F
13D/AChoo Chee Kong3,003,99625.2%+29,250Oct 12, 2026No 13F filer matched
13G/AmDR LTD1,191,52310.0%New 5%+ stakeOct 12, 2026

Institutional Holders — Q3 2026

UBS Group AG38,899
0.0% of portfolio›$32.8K
StoneX Group Inc.26,965
0.0% of portfolio›$24.4K
StyleTurnoverLocationFiled
UBS Group AG
38,899$32.8K0.0%CoreMediumZurich, Switzerland2026-11-10
StoneX Group Inc.
26,965$24.4K0.0%ETFMediumNew York, NY2026-11-03
No 13F filer matched
13D/AChoo Chee Kong3,003,996
25.2% of class · Oct 12, 2026+29,250
No 13F filer matched
13G/AmDR LTD1,191,523
10.0% of class · Oct 12, 2026New 5%+ stake
No 13F filer matched